

## DAFTAR PUSTAKA

- Abudouwayiti, A., et al. (2024) 'HDL levels as a novel predictor of long-term adverse outcomes in patients with heart failure: a retrospective cohort study', *Journal of Inflammation Research*, 17, pp. 6251–6264. doi:10.2147/JIR.S481085
- Aronow, W. (2016) 'Update of treatment of heart failure with reduction of left ventricular ejection fraction', *Archives of Medical Science – Atherosclerotic Diseases*, 1(1), pp. 106–116. doi:10.5114/amsad.2016.63002.
- Aroor, A.R., Mandavia, C.H. and Sowers, J.R. (2012) 'Insulin Resistance and Heart Failure: Molecular Mechanism', *Heart Failure Clinics*, 8(4), pp. 609–617. doi:10.1016/j.hfc.2012.06.005.
- Campbell, P., Krim, S. and Ventura, H. (2015) 'The bi-directional impact of two chronic illnesses: Heart failure and diabetes – a review of the epidemiology and outcomes', *Cardiac Failure Review*, 1(1), p. 8. doi:10.15420/cfr.2015.01.01.8.
- Cheng, P.C., et al. (2019) 'Plasma low-density lipoprotein cholesterol correlates with heart function in individuals with type 2 diabetes mellitus: a cross-sectional study', *Frontiers in Endocrinology*, 10(APR). doi:10.3389/fendo.2019.00234
- Chiu, T.-H. et al. (2021) 'A high triglyceride-glucose index is associated with left ventricular dysfunction and atherosclerosis', *International Journal of Medical Sciences*, 18(4), pp. 1051–1057. doi:10.7150/ijms.53920.
- Dunlay, S.M. et al. (2019) 'Type 2 diabetes mellitus and heart failure: A scientific statement from the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017

ACC/AHA/HFSA Heart Failure Guideline update', *Circulation*, 140(7).  
doi:10.1161/cir.0000000000000691.

Fisher, E.A., et al. (2012) 'HDL function, dysfunction, and reverse cholesterol transport', *Arteriosclerosis, Thrombosis, and Vascular Biology*, 32(12), pp. 2813–2820. doi:10.1161/ATVBAHA

Fujihara, K. et al. (2013) 'Carotid artery plaque and LDL-to-HDL cholesterol ratio predict atherosclerotic status in coronary arteries in asymptomatic patients with type 2 diabetes mellitus', *Journal of Atherosclerosis and Thrombosis*, 20(5), pp. 452–464. doi:10.5551/jat.14977.

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). 'Pathophysiology of type 2 diabetes mellitus', *International Journal of Molecular Sciences* (Vol. 21, Issue 17, pp. 1–34). MDPI AG. <https://doi.org/10.3390/ijms21176275>

Guerrero-Romero, F., et al. (2010) 'The product of triglycerides and glucose, a simple measure of insulin sensitivity: comparison with the euglycemic-hyperinsulinemic clamp', *Journal of Clinical Endocrinology and Metabolism*, 95(7), pp. 3347–3351. doi:10.1210/jc.2010-0288

Hajian-Tilaki, K., Heidari, B., Bakhtiari, A., 2020. Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study. *Casp. J. Intern. Med.* 11: 53–61. doi:10.22088/cjim.11.1.53

Halabi, A., Sen, J., Huynh, Q. & Marwick, T.H. (2020) 'Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-

regression analysis', *Cardiovascular Diabetology*, 19(1). doi:10.1186/s12933-020-01100-w

Han, S., et al. (2022) 'Triglyceride glucose index and its combination with the Get with the Guidelines-Heart Failure score in predicting the prognosis in patients with heart failure', *Frontiers in Nutrition*, 9. doi:10.3389/fnut.2022.950338

Huang, R. et al. (2022) 'Triglyceride–glucose index in the development of heart failure and left ventricular dysfunction: Analysis of the Aric Study', *European Journal of Preventive Cardiology*, 29(11), pp. 1531–1541. doi:10.1093/eurjpc/zwac058.

Jia, G., Hill, M.A. & Sowers, J.R. (2018) 'Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity', *Circulation Research*, 122(4), pp. 624–638. doi:10.1161/CIRCRESAHA.117.311586

Jung, E. et al. (2022) 'Serum cholesterol levels and risk of CARDIOVASCULAR DEATH: A systematic review and a dose-response meta-analysis of prospective cohort studies', *International Journal of Environmental Research and Public Health*, 19(14), p. 8272. doi:10.3390/ijerph19148272.

Kenny, H.C. and Abel, E.D. (2019) 'Heart Failure in Type 2 Diabetes Mellitus: Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies', *Circulation Research. Lippincott Williams and Wilkins*, pp. 121–141. Available at: <https://doi.org/10.1161/CIRCRESAHA.118.311371>.

Khalaji, A. et al. (2023) 'Triglyceride-glucose index and heart failure: A systematic review and meta-analysis', *Cardiovascular Diabetology*, 22(1). doi:10.1186/s12933-023-01973-7.

- Kim, J. et al. (2021) 'Positive association between the ratio of triglycerides to high-density lipoprotein cholesterol and diabetes incidence in Korean adults', *Cardiovascular Diabetology*, 20(1). doi:10.1186/s12933-021-01377-5.
- Kim, W.J.C. et al. (2022) "Beyond Simpson's Rule: Accounting for Orientation and Ellipticity Assumptions," *Ultrasound in Medicine and Biology*, 48(12), pp. 2476–2485. Available at: <https://doi.org/10.1016/j.ultrasmedbio.2022.07.013>.
- Kobayashi, G. et al. (2022) 'Dyslipidemia and 10-year diabetes incidence in Japanese people: Population-based Panasonic Cohort Study 9', *Frontiers in Endocrinology*, 13. doi:10.3389/fendo.2022.957728.
- Kosaraju, A. (2023) Left ventricular ejection fraction, StatPearls [Internet]. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK459131/> (Accessed: 02 December 2024).
- Kosmas, C.E. et al. (2023) 'The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease', *Diagnostics*, 13(5), p. 929. doi:10.3390/diagnostics13050929.
- Kuang, M. et al. (2022) 'Association of LDL:HDL ratio with Prediabetes Risk: A longitudinal observational study based on Chinese adults', *Lipids in Health and Disease*, 21(1). doi:10.1186/s12944-022-01655-5.
- La Canna, G. and Scarfo', I. (2020) 'New and old echographic parameters in heart failure', *European Heart Journal Supplements*, 22(Supplement\_L). doi:10.1093/eurheartj/suaa142.
- Lam, C.S.P., et al. (2018) 'Heart failure with preserved ejection fraction: from mechanisms to therapies', *European Heart Journal*, 39(30), pp. 2780–2792. doi:10.1093/eurheartj/ehy301

- Lazar, S. et al. (2020) ‘Mechanisms of heart failure with preserved ejection fraction in the presence of diabetes mellitus’, *Translational Metabolic Syndrome Research*, 3, pp. 1–5. doi:10.1016/j.tmsr.2020.04.002.
- Lee, J., Yun, J.-S. and Ko, S.-H. (2022) ‘Advanced glycation end products and their effect on vascular complications in type 2 diabetes mellitus’, *Nutrients*, 14(15), p. 3086. doi:10.3390/nu14153086.
- Li, Y. & Li, J. (2023) ‘Analysis of risk factors for heart failure with preserved ejection fraction and observations on blood lipid metabolism’, *Altern Ther Health Med*, 29(8), pp. 396–400. Available at: <https://pubmed.ncbi.nlm.nih.gov/37632969/>
- Liyunxing, Liu, Y., Wang, J., Tian, P. & Liu, P. (2023) ‘High-density lipoprotein and heart failure’, *Reviews in Cardiovascular Medicine*, 24(11). doi:10.31083/j.rcm2411321
- Löfström, U. et al. (2019) “Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction,” *ESC Heart Failure*, 6(4), pp. 830–839. Available at: <https://doi.org/10.1002/ehf2.12458>.
- Longo, M. et al. (2022) “Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues,” *Biomolecules*. MDPI. Available at: <https://doi.org/10.3390/biom12020272>.
- Lund, L.H., et al. (2012) ‘Association between use of renin-angiotensin system antagonists and mortality in patients with heart failure and preserved ejection fraction’, *JAMA*, 308(20), pp. 2108–2117. doi:10.1001/jama.2012.14785

- Mahendra, D. (2025) ‘The role of the four pillars in heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF): how different?’, *Almakki Health Informatics Journal*, 3, pp. 51–59.
- Malmborg, M. et al. (2021) ‘Compliance in primary prevention with statins and associations with cardiovascular risk and death in a low-risk population with type 2 diabetes mellitus’, *Journal of the American Heart Association*, 10(13). doi:10.1161/jaha.120.020395.
- Mapelli, M., Rubbo, F.M., Costantino, S., Amelotti, N. & Agostoni, P. (2025) ‘Pharmacological therapy of HFrEF in 2025: navigating new advances and old unmet needs in an eternal balance between progress and perplexities’, *Cardiac Failure Review*, 11. doi:10.15420/cfr.2024.37
- McDonagh, T. A., Metra, M., Adamo, M., Baumbach, A., Böhm, M., Burri, H., Čelutkienė, J., Chioncel, O., Cleland, J. G. F., Coats, A. J. S., Crespo-Leiro, M. G., Farmakis, D., Gardner, R. S., Gilard, M., Heymans, S., Hoes, A. W., Jaarsma, T., Jankowska, E. A., Lainscak, M., ... Koskinas, K. C. (2021). ‘2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure’, *European Heart Journal* (Vol. 42, Issue 36, pp. 3599–3726). Oxford University Press. <https://doi.org/10.1093/eurheartj/ehab368>
- Mukti, B.H. (2025) ‘Sample size determination: principles and applications for health research’, *Health Sciences International Journal*, 3, pp. 127–144. Available at: <https://doi.org/10.71357/hsij.v3i1.63>
- Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., Matsuo, N., Ichikawa, K., Iwasaki, K., Naito, T., Namba, Y., Yoshida, M., Sugiyama, H., & Ito, H. (2022). ‘Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus,’ *International Journal of*

*Molecular Sciences* (Vol. 23, Issue 7). MDPI.  
<https://doi.org/10.3390/ijms23073587>

Nakamura, M. and Sadoshima, J. (2019) 'Cardiomyopathy in obesity, insulin resistance and diabetes', *The Journal of Physiology*, 598(14), pp. 2977–2993. doi:10.1113/jp276747.

Palazzuoli, A. and Iacoviello, M. (2022) 'Diabetes leading to heart failure and heart failure leading to diabetes: Epidemiological and clinical evidence', *Heart Failure Reviews*, 28(3), pp. 585–596. doi:10.1007/s10741-022-10238-6.

Pandey, A., et al. (2024) 'Association of high-density lipoprotein parameters and risk of heart failure: a multicohort analysis', *JACC: Heart Failure*, 12(7), pp. 1242–1253. doi:10.1016/j.jchf.2024.03.007

Park, J.J. (2021) "Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes," *Diabetes and Metabolism Journal. Korean Diabetes Association*, pp. 146–157. Available at: <https://doi.org/10.4093/DMJ.2020.0282>.

Paulus, W.J. & Tschöpe, C. (2013) 'A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation', *Journal of the American College of Cardiology*, 62(4), pp. 263–271. doi:10.1016/j.jacc.2013.02.092

PERKENI, 2021. Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus tipe 2 di Indonesia 2021.

- Poznyak, A.V., et al. (2021) 'Overview of oxLDL and its impact on cardiovascular health: focus on atherosclerosis', *Frontiers in Pharmacology*, 11. doi:10.3389/fphar.2020.613780
- Rosano, G.M., Vitale, C. and Seferovic, P. (2017) 'Heart failure in patients with diabetes mellitus', *Cardiac Failure Review*, 03(01), p. 52. doi:10.15420/cfr.2016:20:2.
- Roth, G.A. et al. (2023) 'The global burden of heart failure: A systematic analysis for the global burden of disease study 2021', *European Heart Journal*, 44(Supplement\_2). doi:10.1093/eurheartj/ehad655.876.
- Rungratanawanich, W., Qu, Y., Wang, X., Essa, M.M. & Song, B.J. (2021) 'Advanced glycation end products (AGEs) and other adducts in aging-related diseases and alcohol-mediated tissue injury', *Experimental and Molecular Medicine*, 53(2), pp. 168–188. doi:10.1038/s12276-021-00561-7
- Severino, P., et al. (2020) 'Ischemic heart disease and heart failure: role of coronary ion channels', *International Journal of Molecular Sciences*, 21(9). doi:10.3390/ijms21093167
- Simmonds, S.J., Cuijpers, I., Heymans, S. & Jones, E.A.V. (2020) 'Cellular and molecular differences between HFpEF and HFrEF: a step ahead in an improved pathological understanding', *Cells*, 9(1). doi:10.3390/cells9010242
- Smiseth, O.A. et al. (2023) 'Phenotyping heart failure by echocardiography: imaging of ventricular function and haemodynamics at rest and exercise', *European Heart Journal Cardiovascular Imaging*. Oxford University Press, pp. 1329–1342. Available at: <https://doi.org/10.1093/ehjci/jead196>.

- Solomon, S.D., et al. (2019) ‘Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction’, *New England Journal of Medicine*, 381(17), pp. 1609–1620. doi:10.1056/nejmoa1908655
- Sun, T., Chen, M., Shen, H., PingYin, Fan, L., Chen, X., Wu, J., Xu, Z. & Zhang, J. (2022) ‘Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease’, *BMC Cardiovascular Disorders*, 22(1). doi:10.1186/s12872-022-02706-6
- Vitarelli, A. and Gheorghade, M. (2000) “Transthoracic and transesophageal echocardiography in the hemodynamic assessment of patients with congestive heart failure,” *The American Journal of Cardiology*, 86(4, Supplement 1), pp. 36–40. Available at: [https://doi.org/https://doi.org/10.1016/S0002-9149\(00\)00990-5](https://doi.org/https://doi.org/10.1016/S0002-9149(00)00990-5).
- Wang, C. et al. (2022) ‘Association of triglyceride-glucose with cardiac hemodynamics in type 2 diabetes’, *Diabetes and Vascular Disease Research*, 19(2). doi:10.1177/14791641221083396.
- Wang, H. et al. (2023) ‘Association between triglyceride to high-density lipoprotein cholesterol ratio and type 2 diabetes risk in Japanese’, *Scientific Reports*, 13(1). doi:10.1038/s41598-022-25585-5.
- Wang, T., Wang, J., Hu, X., Huang, X. & Chen, G.X. (2020) ‘Current understanding of glucose transporter 4 expression and functional mechanisms’, *World Journal of Biological Chemistry*, 11(3), pp. 76–98. doi:10.4331/wjbc.v11.i3.76
- Wang, T. et al. (2023) ‘Triglyceride-glucose index for the detection of subclinical heart failure with preserved ejection fraction in patients with type 2 diabetes’, *Frontiers in Cardiovascular Medicine*, 10. doi:10.3389/fcvm.2023.1086978.

- Weng, J. *et al.* (2025) ‘High triglyceride-to-high-density lipoprotein cholesterol ratio predicts poor prognosis in new-onset heart failure: A retrospective study’, *BMC Cardiovascular Disorders*, 25(1). doi:10.1186/s12872-025-04706-8.
- Wijnen, M. *et al.* (2021) ‘The effects of antidiabetic agents on heart failure’, *Netherlands Heart Journal*, 30(2), pp. 65–75. doi:10.1007/s12471-021-01579-2.
- Witteles, R.M. and Fowler, M.B. (2008) ‘Insulin-resistant cardiomyopathy: Clinical Evidence, Mechanism, and Treatment Options’, *Journal of the American College of Cardiology*, 51(2), pp. 93–102. doi:10.1016/j.jacc.2007.10.021.
- Wu, B., Zhang, Z., Long, J., Zhao, H. & Zeng, F. (2022) ‘Association between lipoprotein (a) and heart failure with reduced ejection fraction development’, *Journal of Clinical Laboratory Analysis*, 36(1). doi:10.1002/jcla.24083
- Wu, L., Rodriguez, M., el Hachem, K. & Krittanawong, C. (2024) ‘Diuretic treatment in heart failure: a practical guide for clinicians’, *Journal of Clinical Medicine*, 13(15). doi:10.3390/jcm13154470
- Xing, L. *et al.* (2023) ‘High-density lipoprotein and heart failure’, *Reviews in Cardiovascular Medicine*, 24(11). doi:10.31083/j.rcm2411321.
- Zelniker, T.A., *et al.* (2019) ‘SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials’, *The Lancet*, 393(10166), pp. 31–39. doi:10.1016/S0140-6736(18)32590-X



Zhou, Q., et al. (2023) 'High triglyceride-glucose (TyG) index is associated with poor prognosis of heart failure with preserved ejection fraction', *Cardiovascular Diabetology*, 22(1). doi:10.1186/s12933-023-02001-4

Zhou, Y. et al. (2023) 'Association between the triglyceride–glucose index and the risk of mortality among patients with chronic heart failure: Results from a retrospective cohort study in China', *Cardiovascular Diabetology*, 22(1). doi:10.1186/s12933-023-01895-4.